CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project addresses the urgent need for better therapies for non-small cell lung cancer (NSCLC) by identifying new drug targets and developing innovative treatments. It focuses on overcoming resistance to existing therapies and targeting specific genetic mutations.
Lung cancer is the most common cancer fatality in Europe (335000 deaths/yr).
Non-small cell lung cancer (NSCLC) consists 85% of the cases, with 5 yr survival <15%.
Hence, this proposal focuses on the urgent need for better NSCLC therapies.
This is a European problem at societal and scientific level: better therapies are needed to keep the spiralling costs of European health systems under control, and the required expertise (basic science, clinical, biotech, experimental therapeutics) is scattere…
KATHOLIEKE UNIVERSITEIT LEUVEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom, LONDON
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
Spain, Madrid
Type: Research institute
Activity type: Research Organisations
SME: No
Germany, Halle
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
